Rosetta Publishes Data on microRNA-Based Lung Cancer Assay | GenomeWeb

Rosetta Genomics has published data validating its miRview Lung assay as a means to differentiate between the four main types of lung cancer.

The report appeared online last week in the Journal of Molecular Diagnostics.

The assay is based on the expression levels of eight microRNAs, measured using a quantitative RT-PCR platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."